In polypills, as in any recipe, it's ingredients that matter
With great interest we’ve read the position paper of the European Society of Hypertension on the polypill in cardiovascular prevention by Coca et al.. This article correctly outlines the potential benefits of such polypills such as better adherence, reduced drug wasting, and better control of cardiovascular risk factors. Furthermore, the authors briefly touched upon the composition of a polypill, the ‘final issue’ but fail to address the simple issue whether angiotensin-converting enzyme inhibitors (ACEs) still are acceptable ingredients in polypills. We would like to point out that, as in any recipe, it is essentially the ingredients that matter.